Related Experiment Video
Updated: Feb 1, 2026

Author Spotlight: Improving Anesthesia Protocols for Enhanced Mouse Acupuncture Research
Published on: December 8, 2023
Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations
Zubir S Rentiya1, Matthew Wells2, Junun Bae1,2
1Department of Radiology, Neurology, Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract:
Interferons are cytokines that regulate the host's response to viral infection, particularly in the setting of the immunologic response to the hepatitis C virus (HCV). While the virus has the ability to evade the host's innate and specific immunity, exogenous interferon-α with combined ribavirin, treatments have been found to achieve a significant sustained viral response in subgroups of patients with chronic HCV. One of the major side effects of interferon-α is an ocular retinopathy characterized by flame-shaped hemorrhages and cotton wool spots visualized on funduscopic examination. There have been documented cases of more severe side effects including optic nerve and retinal artery damage; however, these instances are the minority. We sought to investigate the literature surrounding interferon-induced retinopathy, clinically correlate our findings with two recent cases, and provide recommendations for practitioners who continue to manage chronic HCV patients using interferon-α with combined ribavirin treatments.
Related Concept Videos
5-Number Summary
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
Discharge Summary Forms
Here's a detailed look at the key components and guidelines for preparing a discharge summary:
Design Consideration
The factor of safety is another key...
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...
Transmission Line Design Considerations
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

